Zai Lab (ZLAB) Rating Increased to Sell at BidaskClub
Zai Lab (NASDAQ:ZLAB) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued to investors on Wednesday.
Several other equities analysts have also issued reports on the company. JPMorgan Chase & Co. assumed coverage on Zai Lab in a research report on Monday, October 16th. They set a “neutral” rating and a $32.00 target price for the company. Citigroup assumed coverage on Zai Lab in a research report on Monday, October 16th. They set a “buy” rating for the company. Finally, Leerink Swann assumed coverage on Zai Lab in a research report on Monday, October 16th. They set an “outperform” rating and a $42.00 target price for the company.
Shares of Zai Lab (NASDAQ:ZLAB) opened at $23.63 on Wednesday. The company has a market capitalization of $1,130.00 and a PE ratio of -23.17. Zai Lab has a 12-month low of $20.67 and a 12-month high of $35.74.
Zai Lab Company Profile
Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases.
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.